Shingles Vaccine May Help Lower Dementia Risk, New Studies Suggest

A growing body of research suggests an unexpected benefit of getting vaccinated for shingles: a potential reduction in the risk of developing dementia, including Alzheimer’s disease. With millions affected by dementia worldwide, scientists are urgently investigating new and accessible ways to lower risk. Here’s what recent studies say about the link between shingles vaccines and cognitive health, including the latest expert insights and recommendations for adults over 50.

Understanding the Connection: Shingles, Vaccines, and Dementia

Shingles is a painful rash caused by the varicella-zoster virus—the same virus responsible for chickenpox. After recovering from chickenpox, the virus can remain dormant in nerve cells for decades, only to reactivate later in life for reasons not yet fully understood. Scientists once viewed shingles as primarily a skin and nerve condition, but new evidence suggests it may have deeper effects—possibly influencing the brain and cognitive function.

• Shingles tends to occur more frequently in people over 50 and those with weakened immune systems.
• Dementia, including Alzheimer’s disease, is a progressive brain disorder impacting memory, thinking, and behavior. Over 55 million people globally live with dementia, with about 10 million new cases every year.

Emerging evidence connects certain viral infections, including those that affect the nerves (like shingles), to an increased risk of dementia. This has led scientists to explore whether preventing shingles through vaccination could in turn reduce dementia risk.

Key Findings: What New Research Shows

Recent large-scale studies have provided some of the most robust evidence to date about the relationship between shingles vaccines and dementia risk:

• Welsh Health Records Study (Stanford Medicine, 2025): An analysis of Welsh older adults revealed that those who received the shingles vaccine were 20% less likely to develop dementia over the next seven years compared to those who were not vaccinated.
  “This huge protective signal was there, any which way you looked at the data.” — Dr. Pascal Geldsetzer, study author
• US Medical Records Analysis: Research examining over 200,000 older Americans showed that the newer recombinant shingles vaccines provided even better protection against dementia than earlier live-attenuated versions.
• The Recombinant Shingles Vaccine (Shingrix) and Dementia Study: Published in Nature Medicine, this natural experiment found a 17% increased time lived without dementia diagnosis among those vaccinated, which translated to an average of 164 additional days without dementia in people who would eventually develop the condition. The protective effect was even stronger in women.

Why Is This Evidence Considered Strong?

Past studies faced criticism because people who choose to get vaccinated often have healthier habits in general—making it hard to know whether the reduced dementia risk was due to the vaccine itself. The recent studies avoided this problem by comparing groups with near-identical health profiles, thanks to unique vaccine rollout policies and sophisticated statistical methods.

Exploring the Science: How Might the Shingles Vaccine Help Prevent Dementia?

Although the link is observational and not conclusively causal, several theories propose ways in which preventing shingles may benefit brain health:

• Inflammation: Viruses like varicella-zoster can inflame blood vessels in the brain, damage nerve cells, and trigger harmful immune responses. Chronic inflammation is a suspected risk factor for dementia.
• Vascular Health: Varicella-zoster has been connected to increased risks of heart disease and stroke, both tied to higher dementia risk.
• Direct Neuronal Damage: The shingles virus may damage nerve tissues directly, possibly accelerating cognitive decline.
• Vaccine’s Role: By preventing shingles infection or reducing its severity, the vaccine may lower the chance of inflammation and neural injury, thus protecting the brain.

It’s important to note that while the vaccine’s effect is statistically significant, it is not a complete prevention. Dementia is a complex disease with many contributing factors, but any intervention that meaningfully reduces risk is considered valuable from a public health standpoint.

Who Should Get the Shingles Vaccine?

• The Centers for Disease Control and Prevention (CDC) recommends the Shingrix vaccine for all adults aged 50 and older, regardless of their history with the older vaccine or past shingles outbreaks.
• Shingrix is administered in two doses, spaced two to six months apart.
• It is safe for most people, with commonly reported mild side effects such as soreness at the injection site, fatigue, and mild fever.

Consult your healthcare provider before vaccination, especially if you have immune system disorders or a history of severe allergies.

Frequently Asked Questions

Does the shingles vaccine prevent Alzheimer’s disease?

Studies show a lower risk of all forms of dementia, but they do not directly prove that the vaccine prevents Alzheimer’s specifically. However, given that Alzheimer’s is the most common cause of dementia, a reduction in overall dementia risk is a meaningful finding.

If I’ve already had shingles or the older vaccine, do I still need Shingrix?

Yes. The CDC recommends Shingrix even for those who previously received the older live-attenuated vaccine (Zostavax) or who have had a shingles outbreak in the past. The recombinant vaccine offers broader and more robust protection.

Are other vaccines linked to lower dementia risk?

Some studies suggest modestly reduced dementia risk with other adult vaccines, such as flu or tetanus boosters, but the effect is smaller than with the recombinant shingles vaccine.

Is the research conclusive?

No. While the connection is convincing and backed by large-scale, well-designed observational studies, only a randomized controlled trial could provide definitive proof. Until then, the evidence is considered “strongly suggestive,” but not absolute.

Expert Opinions: What Do Scientists and Doctors Say?

• Strong Association, Not Absolute Causation: Researchers emphasize that while the links are compelling and consistent across various analyses, observational studies cannot prove causality. However, the recent design of these studies (particularly natural experiments) makes bias less likely.
• Unique Rollout Offered Special Insight: The gradual eligibility of older adults for the vaccine (based on exact birthday cutoffs) offered a rare opportunity to compare nearly identical groups—one eligible, one not—helping to break the association between vaccine uptake and health-conscious behavior.
• Room for Future Research: Experts call for deeper studies, including laboratory research to uncover the biological mechanisms and clinical trials to establish firm causality.

“If further confirmed, the new findings suggest that a preventive intervention for dementia is already close at hand.” — Stanford Medicine Research Team

What This Means for You

For adults aged 50 and older, the shingles vaccine already offers proven protection against painful and potentially serious shingles outbreaks. The possibility that it may also lower dementia risk provides yet another compelling reason to get vaccinated.

With no cure for Alzheimer’s and limited ways to reduce dementia risk, vaccines are a practical, doctor-supported tool in the wider toolkit for aging well. Older adults and caregivers are encouraged to discuss the shingles vaccine with healthcare providers, not just for nerve and skin health, but as a sensible step for brain health, too.

• Vaccination remains essential even if you maintain a healthy lifestyle—diet, exercise, and managing other health factors remain important for long-term brain wellness.

Action Steps: How to Protect Yourself

• Ask your doctor if you’re eligible for the shingles vaccine (Shingrix), especially if you are over 50.
• Discuss your health history, other vaccinations, and potential allergic reactions at your next medical appointment.
• Maintain regular checkups, and stay informed about new research on aging and brain health.

Key Takeaways

• The Shingrix vaccine is recommended for adults aged 50+ for effective shingles prevention and may offer the added benefit of reducing dementia risk.
• Current research shows a 17–20% lower risk of dementia over six to seven years for those vaccinated with recombinant shingles vaccines.
• The protective effect applies to both men and women, and is slightly stronger in women.
• Preventive strategies, including vaccination, offer hope in reducing the growing burden of cognitive decline in aging populations.

References and Further Reading

• Stanford Medicine News. “Shingles vaccination linked to lower dementia risk” (2025).
• Nature Medicine. “The recombinant shingles vaccine is associated with lower risk of dementia” (2024).
• Alzheimer’s Information. “Shingles Vaccine May Cut Alzheimer’s Risk” (2024).